11:45 AM EST - 3D Signatures Inc. : Announced its participation in a major clinical trial for prostate cancer diagnosis and management known as PRECISE. This trial marks the Company's first step toward validation and approval of clinical risk assessment tests for prostate cancer. 3D Signatures Inc.
shares V.DXD are trading down $0.03 at $0.60.
